A pulmonary specialist shares his approach to treating patients with bronchiectasis, highlighting gaps in knowledge that impact management practices. What are the current gaps in knowledge regarding ...
One woman's journey from an unexpected diagnosis to learning how to manage a chronic, progressive lung disease.
Non-cystic fibrosis bronchiectasis (NCFB) is a heterogeneous disease characterised by a ‘vicious vortex’ of ...
CHAPEL HILL, N.C. & MIAMI--(BUSINESS WIRE)--Renovion and COPD Foundation Joint Release – Renovion, Inc. has announced that the first patient has been enrolled in a Phase 2 clinical study evaluating ...
Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...
Please provide your email address to receive an email when new articles are posted on . From weeks 17 to 62 of treatment, azithromycin was highly effective in children with bronchiectasis. Birth ...
—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J., Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (INSM), a ...
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic ...
— BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — BRIDGEWATER, N.J., Nov. 18, 2025 /PRNewswire/ -- Insmed Incorporated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback